GLS 010

Drug Profile

GLS 010

Alternative Names: GLS-010; WBP3055

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Harbin Gloria Pharmaceuticals; WuXi Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 18 Aug 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 17 Aug 2017 WuXi Biologics, Harbin Gloria Pharmaceuticals and Arcus Biosciences agree to co-promote and co-develop GLS 010 in North America, Europe, Japan and certain other territories for Cancer
  • 17 Aug 2017 Phase-I clinical trials in Cancer in China (Parenteral), before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top